NASDAQ:RPHM - Reneo Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.75
  • Forecasted Upside: 394.31 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.03
▼ -0.69 (-8.94%)

This chart shows the closing price for RPHM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reneo Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPHM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPHM

Analyst Price Target is $34.75
▲ +394.31% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Reneo Pharmaceuticals in the last 3 months. The average price target is $34.75, with a high forecast of $45.00 and a low forecast of $24.00. The average price target represents a 394.31% upside from the last price of $7.03.

This chart shows the closing price for RPHM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Reneo Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2021LADENBURG THALM/SH SHInitiated CoverageBuy$45.00Medium
5/23/2021SVB LeerinkReiterated RatingBuy$25.00Low
5/4/2021SVB LeerinkInitiated CoverageOutperform$25.00Low
5/4/2021Jefferies Financial GroupInitiated CoverageBuy$24.00Low
5/4/2021Piper SandlerInitiated CoverageOverweight$45.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Reneo Pharmaceuticals logo
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.03
Low: $6.91
High: $7.51

50 Day Range

MA: $7.42
Low: $6.31
High: $8.85

52 Week Range

Now: $7.03
Low: $6.10
High: $17.18

Volume

15,482 shs

Average Volume

68,323 shs

Market Capitalization

$171.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Reneo Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Reneo Pharmaceuticals in the last twelve months: Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for RPHM.

What is the current price target for Reneo Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Reneo Pharmaceuticals in the last year. Their average twelve-month price target is $34.75, suggesting a possible upside of 394.3%. LADENBURG THALM/SH SH has the highest price target set, predicting RPHM will reach $45.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $24.00 for Reneo Pharmaceuticals in the next year.
View the latest price targets for RPHM.

What is the current consensus analyst rating for Reneo Pharmaceuticals?

Reneo Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RPHM will outperform the market and that investors should add to their positions of Reneo Pharmaceuticals.
View the latest ratings for RPHM.

How do I contact Reneo Pharmaceuticals' investor relations team?

The company's listed phone number is 858-283-0280 and its investor relations email address is [email protected] The official website for Reneo Pharmaceuticals is reneopharma.com.